Country: Ամերիկայի Միացյալ Նահանգներ
language: անգլերեն
source: NLM (National Library of Medicine)
TOLVAPTAN (UNII: 21G72T1950) (TOLVAPTAN - UNII:21G72T1950)
Apotex Corp.
ORAL
PRESCRIPTION DRUG
Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. It has not been established that raising serum sodium with tolvaptan tablets provides a symptomatic benefit to patients. Tolvaptan tablets are contraindicated in the following conditions: - Patients with autosomal dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS [see Warnings and Precautions (5.2)] - Unable to sense or respond to thirst - Hypovolemic hyponatremia - Taking strong CYP3A inhibitors [see Warnings and Precautions (5.5)] - Anuria - Hypersensitivity (e.g., anaphylactic shock, rash gen
How Supplied Tolvaptan tablets are available in the following strengths and packages. Tolvaptan 15 mg tablets are non-scored, blue, triangular, shallow-convex, debossed with "OTSUKA" and "15" on one side. Tolvaptan 30 mg tablets are non-scored, blue, round, shallow-convex, debossed with "OTSUKA" and "30" on one side. Storage and Handling Store at 25°C (77°F), excursions permitted between 15°C and 30°C (59°F to 86°F) [see USP controlled Room Temperature]. Keep out of reach of children.
New Drug Application Authorized Generic
Apotex Corp. ---------- MEDICATION GUIDE TOLVAPTAN TABLETS (TOL-VAP-TAN) Read the Medication Guide that comes with tolvaptan tablets before you take it and each time you get a new prescription. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. Share this important information with members of your household. What is the most important information I should know about tolvaptan tablets? 1) Tolvaptan tablets may make the salt (sodium) level in your blood rise too fast. This can increase your risk of a serious condition called osmotic demyelination syndrome (ODS). ODS can lead to coma or death. ODS can also cause new symptoms such as: • trouble speaking • swallowing trouble or feeling like food or liquid gets stuck while swallowing • drowsiness • confusion • mood changes • trouble controlling body movement (involuntary movement) and weakness in muscles of the arms and legs • seizures You or a family member should tell your healthcare provider right away if you have any of these symptoms even if they begin later in treatment. Also tell your healthcare provider about any other new symptoms while taking tolvaptan tablets. You may be more at risk for ODS if you have: • liver disease • not eaten enough for a long period of time (malnourished) • very low sodium level in your blood • been drinking large amounts of alcohol for a long period of time (chronic alcoholism) To lessen your risk of ODS while taking tolvaptan tablets: • Treatment with tolvaptan tablets should be started and re-started only in a hospital, where the sodium levels in your blood can be checked closely. • Do not take tolvaptan tablets if you cannot tell if you are thirsty. • To prevent losing too much body water (dehydration), have water available to drink at all times while taking tolvaptan tablets. Unless your healthcare provider tells you otherwise, drink when you are thirsty. • If your healthcare provider tells read_full_document
TOLVAPTAN- TOLVAPTAN TABLET APOTEX CORP. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TOLVAPTAN TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TOLVAPTAN TABLETS. TOLVAPTAN TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2009 WARNING: (A) INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM (B) NOT FOR USE FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ (A) INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM TOLVAPTAN TABLETS SHOULD BE INITIATED AND RE-INITIATED IN PATIENTS ONLY IN A HOSPITAL WHERE SERUM SODIUM CAN BE MONITORED CLOSELY. TOO RAPID CORRECTION OF HYPONATREMIA (E.G., >12 MEQ/L/24 HOURS) CAN CAUSE OSMOTIC DEMYELINATION RESULTING IN DYSARTHRIA, MUTISM, DYSPHAGIA, LETHARGY, AFFECTIVE CHANGES, SPASTIC QUADRIPARESIS, SEIZURES, COMA AND DEATH. IN SUSCEPTIBLE PATIENTS, INCLUDING THOSE WITH SEVERE MALNUTRITION, ALCOHOLISM OR ADVANCED LIVER DISEASE, SLOWER RATES OF CORRECTION MAY BE ADVISABLE. (B) NOT FOR USE FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) BECAUSE OF THE RISK OF HEPATOTOXICITY, TOLVAPTAN SHOULD NOT BE USED FOR ADPKD OUTSIDE OF THE FDA-APPROVED REMS (4) RECENT MAJOR CHANGES Warnings and Precautions (5.5, 5.7) 04/2021 INDICATIONS AND USAGE Tolvaptan tablets are selective vasopressin V -receptor antagonists indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia [serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction], including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH) (1) _Limitations of Use:_ Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets (1) It has not been established that tolvaptan tablets provide a symptomatic benefit to patients (1) DOSAGE read_full_document